Novartis Shares Down as Failed Cholesterol Drug Study Increases Pipeline Pressure
8 Articles
8 Articles
Novartis shares down as failed cholesterol drug study increases pipeline pressure
LONDON, Sept 7 (Reuters) - Shares of Novartis fell 3.3% on Monday morning after its cholesterol drug failed in a closely watched study, casting fresh doubt on the therapeutic approach and raising the stakes for the Swiss drugmaker's upcoming data...
Reformatorisch Dagblad
welingelichtekringen.nlNovartis lost more than 3 percent of its market value on the Zurich stock exchange on Monday. The Swiss pharmaceutical company suffered a second setback in its drug research within a week, after a promising heart medication turned out not to work as well as expected in an advanced study. Investors were shocked by this.
This failure marks a major setback to hopes that the drug would usher in a new approach to preventing cardiovascular disease.
AMSTERDAM (ANP/BLOOMBERG) - Novartis lost more than 3 percent in market value on the Zurich stock exchange on Monday. The Swiss pharmaceutical company suffered a second setback in its drug research within a week, after a promising heart drug was discovered in an advanced study.
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
